As social-media hype around drugs like Ozempic and Mounjaro explodes, patient testimonies have focused not only on the dramatic effect on their waistlines, but also on how quickly many seem to pack the pounds back on if they stop taking the injections. That may not be ideal for patients, but for Wall Street it is a feature rather than a bug. Nothing gets investors more hyped up than a product whose target market is massive—more than 40% of American adults are obese—and that also needs to be taken indefinitely.
Read the full article: Obesity Could Be Pharma’s Biggest Blockbuster Yet //
Source: https://www.wsj.com/articles/ozempic-wegovy-mounjaro-obesity-lilly-novo-nordisk-blockbuster-9b285303